ALX ONCOLOGY HOLDINGS INC Operating Cash Flow
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Operating Cash Flow of -$34.70 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- ALX ONCOLOGY HOLDINGS INC net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$16.06M.
- ALX ONCOLOGY HOLDINGS INC net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$18.65M.
- ALX ONCOLOGY HOLDINGS INC net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$18.98M.
- ALX ONCOLOGY HOLDINGS INC net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$17.09M.
- ALX ONCOLOGY HOLDINGS INC net cash provided by (used in) operating activities for fiscal 2025 was -$84.14M.
- ALX ONCOLOGY HOLDINGS INC net cash provided by (used in) operating activities for fiscal 2024 was -$121.91M.
- ALX ONCOLOGY HOLDINGS INC net cash provided by (used in) operating activities for fiscal 2023 was -$130.36M.
- ALX ONCOLOGY HOLDINGS INC net cash provided by (used in) operating activities for fiscal 2022 was -$89.22M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$16.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$34.70M 10-Q · filed 2026-08-06 | -$53.69M derived: sum of 3 quarters · filed 2026-08-06 | -$70.78M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$18.65M 10-Q · filed 2026-05-08 | -$37.63M derived: sum of 2 quarters · filed 2026-05-08 | -$54.72M derived: sum of 3 quarters · filed 2026-05-08 | -$78.13M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$18.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$36.07M derived: sum of 2 quarters · filed 2026-03-09 | -$59.48M derived: sum of 3 quarters · filed 2026-08-06 | -$84.14M 10-K · filed 2026-03-09 |
| 2025-09-30 | -$17.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$40.50M derived: sum of 2 quarters · filed 2026-08-06 | -$65.16M 10-Q · filed 2025-11-07 | -$97.21M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$23.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$48.07M 10-Q · filed 2026-08-06 | -$80.11M derived: sum of 3 quarters · filed 2026-08-06 | -$105.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$24.66M 10-Q · filed 2026-05-08 | -$56.71M derived: sum of 2 quarters · filed 2026-05-08 | -$82.08M derived: sum of 3 quarters · filed 2026-05-08 | -$108.65M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$32.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$57.42M derived: sum of 2 quarters · filed 2026-03-09 | -$83.99M derived: sum of 3 quarters · filed 2026-03-09 | -$121.91M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$25.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$51.94M derived: sum of 2 quarters · filed 2025-11-07 | -$89.87M 10-Q · filed 2025-11-07 | -$129.54M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-06-30 | -$26.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$64.49M 10-Q · filed 2025-08-12 | -$104.17M derived: sum of 3 quarters · filed 2026-03-09 | -$135.33M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-03-31 | -$37.92M 10-Q · filed 2025-05-08 | -$77.60M derived: sum of 2 quarters · filed 2026-03-09 | -$108.76M derived: sum of 3 quarters · filed 2026-03-09 | -$140.47M derived: sum of 4 quarters · filed 2026-03-09 |
| 2023-12-31 | -$39.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$70.84M derived: sum of 2 quarters · filed 2026-03-09 | -$102.55M derived: sum of 3 quarters · filed 2026-03-09 | -$130.36M 10-K · filed 2026-03-09 |
| 2023-09-30 | -$31.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$62.87M derived: sum of 2 quarters · filed 2024-11-07 | -$90.69M 10-Q · filed 2024-11-07 | -$111.35M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | -$31.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$59.53M 10-Q · filed 2024-08-12 | -$80.19M derived: sum of 3 quarters · filed 2025-03-06 | -$111.08M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | -$27.82M 10-Q · filed 2024-05-09 | -$48.48M derived: sum of 2 quarters · filed 2025-03-06 | -$79.37M derived: sum of 3 quarters · filed 2025-03-06 | -$96.36M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | -$20.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$51.55M derived: sum of 2 quarters · filed 2025-03-06 | -$68.55M derived: sum of 3 quarters · filed 2025-03-06 | -$89.22M 10-K · filed 2025-03-06 |
| 2022-09-30 | -$30.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$47.88M derived: sum of 2 quarters · filed 2023-11-13 | -$68.56M 10-Q · filed 2023-11-13 | -$86.04M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-06-30 | -$17.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$37.67M 10-Q · filed 2023-08-10 | -$55.16M derived: sum of 3 quarters · filed 2024-03-07 | -$80.02M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-03-31 | -$20.67M 10-Q · filed 2023-05-11 | -$38.16M derived: sum of 2 quarters · filed 2024-03-07 | -$63.02M derived: sum of 3 quarters · filed 2024-03-07 | -$83.64M derived: sum of 4 quarters · filed 2024-03-07 |
| 2021-12-31 | -$17.49M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$42.34M derived: sum of 2 quarters · filed 2024-03-07 | -$62.97M derived: sum of 3 quarters · filed 2024-03-07 | -$68.10M 10-K · filed 2024-03-07 |
| 2021-09-30 | -$24.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$45.48M derived: sum of 2 quarters · filed 2022-11-08 | -$50.61M 10-Q · filed 2022-11-08 | -$64.23M derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-06-30 | -$20.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$25.76M 10-Q · filed 2022-08-08 | -$39.37M derived: sum of 3 quarters · filed 2023-03-09 | -$48.92M derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-03-31 | -$5.13M 10-Q · filed 2022-05-09 | -$18.75M derived: sum of 2 quarters · filed 2023-03-09 | -$28.30M derived: sum of 3 quarters · filed 2023-03-09 | -$34.46M derived: sum of 4 quarters · filed 2023-03-09 |
| 2020-12-31 | -$13.62M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$23.16M derived: sum of 2 quarters · filed 2023-03-09 | -$29.33M derived: sum of 3 quarters · filed 2023-03-09 | -$38.29M 10-K · filed 2023-03-09 |
| 2020-09-30 | -$9.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$15.71M derived: sum of 2 quarters · filed 2021-11-12 | -$24.67M 10-Q · filed 2021-11-12 | -$27.55M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$6.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$15.13M 10-Q · filed 2021-08-12 | -$18.00M derived: sum of 3 quarters · filed 2022-02-28 | -$21.19M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$8.96M 10-Q · filed 2021-05-17 | -$11.84M derived: sum of 2 quarters · filed 2022-02-28 | -$15.02M derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | -$2.87M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$6.06M derived: sum of 2 quarters · filed 2022-02-28 | -$14.25M 10-K · filed 2022-02-28 | |
| 2019-09-30 | -$3.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$11.38M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | -$8.19M 10-Q · filed 2020-08-27 | |||
| 2018-12-31 | -$13.19M 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |